Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-idiotype cancer vaccine 3H1 - Titan

Drug Profile

Anti-idiotype cancer vaccine 3H1 - Titan

Alternative Names: 3H1; Anti-idiotype antibody 3H1; Anti-idiotype CEA antibody vaccine - Titan Pharmaceuticals; CeaVac

Latest Information Update: 26 Aug 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Titan Pharmaceuticals
  • Class Cancer vaccines; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Non-small cell lung cancer

Most Recent Events

  • 26 Aug 2004 Discontinued - Phase-II for Breast cancer in USA (unspecified route)
  • 26 Aug 2004 Discontinued - Phase-II for Non-small cell lung cancer in USA (Parenteral)
  • 26 Aug 2004 Discontinued - Phase-III for Colorectal cancer in Denmark (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top